**
In a startling turn of events, a routine visit to the optician led Jez Bridges, a 59-year-old father of four from Stourbridge, to a terminal diagnosis of uveal melanoma, a rare form of eye cancer. This case underscores the critical role that regular eye examinations play in identifying serious health issues, given that many individuals with ocular melanoma exhibit no symptoms until the disease has progressed significantly.
A Shocking Diagnosis
In July 2025, after seeking new reading glasses, Mr Bridges underwent an optical coherence tomography (OCT) scan during his eye test, which revealed a small mole at the back of his left eye. Initially, he did not grasp the potential implications of this finding. “It didn’t really mean anything to me then,” he reflected. The revelation of the mole was a surprise, as he had been asymptomatic, a scenario not uncommon for those afflicted with ocular melanoma, which affects approximately 750 individuals annually in the UK.
The absence of symptoms can delay diagnosis, often until the cancer has reached an advanced stage. In Mr Bridges’ case, six months after his initial diagnosis, follow-up scans indicated that the cancer had metastasised to his liver, placing him in a dire situation with a prognosis of just two years to live.
The Financial Burden of Treatment
Faced with a bleak outlook, Mr Bridges has been compelled to raise £200,000 for a private treatment known as chemosaturation—a highly specialised therapy aimed at targeting liver metastases from ocular melanoma. This procedure, unavailable on the NHS, costs approximately £40,000 per session and may require up to five treatments. Chemosaturation involves isolating the affected organ and applying chemotherapy directly to it, with clinical trials suggesting a 90% efficacy rate for patients.
Despite the promising results associated with this treatment, the National Institute for Health and Care Excellence (NICE) has expressed reservations regarding its safety and efficacy, recommending its use with careful oversight. This regulatory uncertainty complicates the situation for patients like Mr Bridges, who are forced to navigate a complex healthcare landscape where private funding may be the only option for potentially life-saving treatments.
The Emotional Toll
As he campaigns for financial support, Mr Bridges speaks candidly about the emotional strain this diagnosis has placed on him and his family. He envisions moments he hopes to witness, such as celebrating milestones with his children and eventually holding his grandchildren. “It sounds dramatic, but I want to enjoy the time I have left,” he stated, as he has managed to raise £64,000 so far through a GoFundMe page.
His story reflects a broader issue within the healthcare system, where the financial burden of necessary treatments can weigh heavily on families already grappling with the emotional distress of a cancer diagnosis. The need for accessible and effective treatment options is paramount, as Mr Bridges exemplifies the urgent need for better support systems for patients facing similar challenges.
The Importance of Regular Eye Tests
This case highlights the critical need for regular eye examinations. The potential for serious conditions to remain undetected underscores the value of proactive health measures. Ocular melanoma may lead to vision changes such as blurred vision or flashes of light, but many individuals, like Mr Bridges, may show no signs at all. Regular screening could be life-saving; as Mr Bridges noted, “I wouldn’t know if I hadn’t had that eye test.”
In a healthcare climate where early detection can significantly influence treatment outcomes, this incident serves as a reminder that routine check-ups are not merely optional but essential.
Why it Matters
Mr Bridges’ experience serves as a poignant reminder of the imperative for regular health screenings and the need for accessible, effective treatment options for all patients. As the healthcare system continues to evolve, it is crucial to address the gaps in care that leave patients vulnerable, particularly when confronting rare and aggressive forms of cancer. His case calls for an urgent reevaluation of how we support individuals facing life-threatening diagnoses, ensuring that financial constraints do not dictate access to life-saving treatments.
